Free Trial

Nektar Therapeutics (NKTR) News Today

Nektar Therapeutics logo
$0.70 +0.02 (+3.68%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.71 +0.01 (+1.82%)
As of 07:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NKTR Latest News

Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Position Boosted by Woodline Partners LP
Woodline Partners LP lifted its holdings in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 187.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,974,512 shares of the biopharmaceutical company's stock after pur
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Buy" from Brokerages
Shares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have received an average recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommend
Nektar Therapeutics stock logo
Shay Capital LLC Sells 1,243,072 Shares of Nektar Therapeutics (NASDAQ:NKTR)
Shay Capital LLC lessened its holdings in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 77.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 352,204 shares of the biopharmaceutical company's stock after selling 1,243,072 shares during the peri
Nektar Therapeutics stock logo
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in Nektar Therapeutics (NASDAQ:NKTR)
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 37.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,580,916 shares of the biopharmaceutical co
Nektar Therapeutics stock logo
Equities Analysts Offer Predictions for NKTR Q2 Earnings
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued on Monday, May 12th. HC Wainwright analyst A. He now anticipates that the biopharmaceutical company will
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Given "Market Perform" Rating at William Blair
William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a report on Monday.
Nektar Therapeutics stock logo
Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at B. Riley reduced their Q1 2025 earnings estimates for Nektar Therapeutics in a research report issued on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of ($0.
Nektar Therapeutics stock logo
Deep Track Capital LP Reduces Stock Position in Nektar Therapeutics (NASDAQ:NKTR)
Deep Track Capital LP trimmed its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 87.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,975,998 shares of the biopharmaceutical compa
Nektar Therapeutics
Nektar Therapeutics stock logo
22Nw LP Takes Position in Nektar Therapeutics (NASDAQ:NKTR)
22Nw LP acquired a new position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 2,191,750 shares of the biopharmaceutical company's stock, valued at approximately $2,038,000. Nektar Therapeutics makes up
Nektar Therapeutics stock logo
Nektar Therapeutics (NKTR) to Release Earnings on Thursday
Nektar Therapeutics (NASDAQ:NKTR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-nektar-therapeutics-stock/)
Nektar Therapeutics stock logo
Nantahala Capital Management LLC Acquires 3,700,000 Shares of Nektar Therapeutics (NASDAQ:NKTR)
Nantahala Capital Management LLC increased its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 90.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,810,000 shares of the biopharmaceutical
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of "Buy" from Analysts
Shares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have been given an average rating of "Buy" by the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy
Nektar Therapeutics stock logo
Renaissance Technologies LLC Raises Stock Position in Nektar Therapeutics (NASDAQ:NKTR)
Renaissance Technologies LLC grew its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 17.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,910,786 shares of the biopharmaceutical company's
Nektar Therapeutics stock logo
Diadema Partners LP Acquires New Holdings in Nektar Therapeutics (NASDAQ:NKTR)
Diadema Partners LP purchased a new stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 698,919 shares of the biopharmaceutical company's stock, valued at appr
Nektar Therapeutics stock logo
Altium Capital Management LLC Raises Holdings in Nektar Therapeutics (NASDAQ:NKTR)
Altium Capital Management LLC raised its position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 26,172.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,000,000 shares of the biopharmaceutical company's stock after purchasing
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at StockNews.com
StockNews.com initiated coverage on Nektar Therapeutics in a research note on Wednesday. They issued a "hold" rating on the stock.
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the stock from $1.00 to $2.00 in a report on Friday.
Nektar management to meet virtually with B. Riley
Nektar upgraded to Buy from Hold at Jefferies
Nektar Therapeutics stock logo
Equities Analysts Set Expectations for NKTR Q1 Earnings
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per
Nektar Therapeutics stock logo
Q1 Earnings Estimate for NKTR Issued By Zacks Research
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. Zacks Research analyst K. Das forecasts
Nektar Therapeutics stock logo
Traders Buy Large Volume of Call Options on Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders acquired 2,351 call options on the stock. This represents an increase of approximately 245% compared to the typical volume of 681 call options.
Nektar files $300M mixed securities shelf
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
Nektar management to meet with Piper Sandler
Get Nektar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

NKTR Media Mentions By Week

NKTR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NKTR
News Sentiment

0.38

0.87

Average
Medical
News Sentiment

NKTR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NKTR Articles
This Week

6

4

NKTR Articles
Average Week

Get Nektar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners